Ocugen (OCGN) Stock Analysis & AI Equity Report
Ocugen (OCGN) overview
Ocugen (OCGN) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 4.4m and operating profit of USD -62.9m; the year-end share price was 1.35 USD and market capitalisation was USD 422m. Ocugen is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Ocugen's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Ocugen
Ocugen develops gene therapies for blindness-causing diseases using its modifier gene therapy platform. Its late-stage programs include OCU400 for retinitis pigmentosa, with Phase 3 liMeliGhT data expected in 2027; OCU410ST for Stargardt disease, in a Phase 2/3 pivotal trial; and OCU410 for geographic atrophy, now in Phase 3. The company also works with regional partners to expand potential patient access to OCU400.
Generate the Ocugen report
Ocugen is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Ocugen and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Ocugen
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.